Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLG-MCL5 (MARiT)
2011-001557-85Phase 2Suspended
- Sponsor
- Nordic Lymphoma Group
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and cytarabine in mantle cell lymphoma (MCL), sponsored by Nordic Lymphoma Group. Primary endpoint: Complete remission pretransplant. Started Jun 2011; status: suspended.
02
Drugs
rituximabcytarabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2011-001557-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001557-85.